OPL.AU · Opyl Limited

-

Please sign in to comment on OPL.AU

1 Comment

Admin

4 years, 1 month ago

Opyl Limited is currently in a long term uptrend where the price is trading 9.5% above its 200 day moving average.

From a valuation standpoint, the stock is 97.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 7.8.

Opyl Limited's total revenue rose by 32.9% to $487K since the same quarter in the previous year.

Its net income has increased by 102.6% to $22K since the same quarter in the previous year.

Finally, its free cash flow grew by 102.0% to $8K since the same quarter in the previous year.

Based on the above factors, Opyl Limited gets an overall score of 5/5.

Exchange	AU
CurrencyCode	AUD
ISIN	AU0000070856
Sector	Healthcare
Industry	Health Information Services

PE Ratio	None
Target Price	None
Beta	1.1
Market Cap	4M
Dividend Yield	None

ABOUT

Opyl Limited

Opyl Limited engages in the development of digital tools that enhance healthcare experience for patients in Australia. The company offers TrialKey, an AI-driven clinical trial optimization and success prediction platform, that simulate and optimize trial designs for pharmaceuticals, medical devices, alternative therapies, and novel conditions. It also provides TrialGen, an AI-powered tool streamlines clinical trial design process for biopharma, MedTech, government, and healthcare organizations. The company was formerly known as ShareRoot Limited and changed its name to Opyl Limited in December 2019. Opyl Limited was incorporated in 1994 and is based in Milsons Point, Australia.

OPL.AU · Opyl Limited

-

Opyl Limited

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest Opyl Limited using a moving average strategy